Last reviewed · How we verify
NCT07233876
DuoCor 2 DOMINATE Study
NA trial testing DuoCor Ventricular Assist System in Advanced Heart Failure in 50 participants. Not yet recruiting.
1 October 2027
Quick facts
| Lead sponsor | Shenzhen Core Medical Technology CO.,LTD. |
|---|---|
| Phase | NA |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 50 |
| Start date | 1 April 2026 |
| Primary completion | 1 October 2027 |
| Estimated completion | 1 April 2029 |
| Sites | 1 location across Germany |
Drugs / interventions tested
- DuoCor Ventricular Assist System
Conditions studied
- Advanced Heart Failure — all drugs for Advanced Heart Failure →
Sponsor
Shenzhen Core Medical Technology CO.,LTD.
Who can join
Adults 18 to 75, any sex, with Advanced Heart Failure. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Advanced heart failure is a life-threatening condition characterized by the inability of one or both ventricles to maintain adequate blood circulation. In such cases, medical treatments often prove ineffective, necessitating advanced treatment. Heart transplantation is the standard treatment for these patients, but it is severely limited by the shortage of donor hearts. As a result, mechanical circulatory support (MCS) devices are often employed. However, the most common form, the left ventricular assist device (LVAD), is only suitable for patients with isolated left ventricular dysfunction. This leaves a significant treatment gap for patients with biventricular failure. For this population, current options, such as total artificial hearts (TAHs) and biventricular assist devices (BiVADs), are associated with significant challenges, including high rates of adverse events and suboptimal long-term outcomes. The DuoCor Ventricular Assist System (VAS) is a next-generation MCS device specifically developed to address this need by providing simultaneous biventricular support. It incorporates two compact, good hemocompatible blood pumps designed for implantation in both the left and right heart, controlled via a single driveline and external controller. It aims to reduce surgical complexity, improve patient mobility, and minimize complications such as thrombosis and infection. The primary objective of this study is to evaluate the safety and efficacy of the DuoCor VAS as a treatment for advanced biventricular heart failure.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07233876
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of DuoCor Ventricular Assist System
Trials testing the same drug.
- NCT06878508 — DuoCor Ventricular Assist System Early Feasibility Study · NA · recruiting
Other recruiting trials for Advanced Heart Failure
Currently open trials in the same condition.
- NCT07497308 — GDF-15 and Early Outcomes After LVAD Implantation · recruiting
Other Shenzhen Core Medical Technology CO.,LTD. trials
Trials by the same sponsor.
- NCT06886113 — CorVad Myocardial Infarction Complicated with Cardiogenic Shock Trial · NA · not yet recruiting
- NCT06646224 — Efficacy and Safety of the CorVad Percutaneous Ventricular Assist System in Cardiogenic Shock · NA · recruiting
- NCT06878508 — DuoCor Ventricular Assist System Early Feasibility Study · NA · recruiting
- NCT05876000 — Corheart 6 LVAS Study · NA · recruiting
- NCT06373120 — Interventional Ventricular Assist System for PCI in CHIP Patients · NA · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07233876 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Shenzhen Core Medical Technology CO.,LTD.
- Last refreshed: 18 November 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07233876.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing